Collaboration with Babraham Institute to explore PI3 kinase inhibitors in the treatment of inflammatory diseases

Southampton, UK, 17 December 2012 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that it has entered into a collaboration with the Babraham Institute (Cambridge, UK), to further characterize novel treatments for inflammatory diseases through the regulation of phosphatidylinositol-3-kinase (PI3K) – a family of enzymes important […]